Search clinical trials for: ABT-493, ABT-530

Total 4378 results

Sorlandet Hospital HF
University of Oslo; Karolinska Institutet; University of Oxford; The Hospital of... and other collaborators

Completed

Secondary Prevention of Depression Through Group-based ACT-Therapy Preceded by an Experimental ABM-Procedure

Major Depression

Norway
Veterans Medical Research Foundation
National Institute of Mental Health (NIMH)

Completed

Assertive Community Treatment With CBT and SST for Schizophrenia

Schizophrenia

United States
Tel Aviv University

Completed

ACT With Feedback for Post Traumatic Stress Disorder (PTSD)

PTSD

Israel
University of Alabama at Birmingham

Completed

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Brain Tumor

United States
Joseph Brant Hospital

Unknown

Triple Aim Psychotherapy: Aimed at Improving Patient Experience, Population Health, and Cost (TAP)

Depressive Symptoms | Anxiety Symptoms

Canada
The University of Hong Kong
The Hong Kong Jockey Club Charities Trust; Hong Kong Young Women's Christian... and other collaborators

Recruiting

Acceptance and Commitment Therapy and Exercise for Older Adults With Chronic Pain

Chronic Pain | Exercise | Older Adults | Acceptance and Commitment Therapy | Psychosocial Intervention | Art

Hong Kong
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Chronic Hepatitis C Infection
University of Wisconsin, Madison
National Institute of Mental Health (NIMH)

Not yet recruiting

Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons

Depression | Anxiety Disorders | Anxiety | Depression, Anxiety
University of Alcala
Hospital Universitario Principe de Asturias

Completed

Predictors and Moderators of Cognitive-Behavioral Therapy and Acceptance and Commitment Therapy for Panic Disorder

Panic Disorder | Acceptance and Commitment Therapy | Predictor | Cognitive-Behavioral Therapy

Spain
The Miriam Hospital

Unknown

Project CORE: Disseminating Eating Disorders Treatment

Eating Disorders in Adolescence | Anorexia Nervosa/Bulimia | Anorexia Nervosa Restricting Type

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
Abbott

Completed

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

Schizophrenia

United States
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
King Faisal University
Mansoura University

Completed

Non-dependent Lung High Frequency Positive Pressure Ventilation (HFPPV) and Right Ventricular Function

Lung Diseases | Esophageal Diseases

Egypt
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection

Chronic Hepatitis C Infection
AbbVie

Completed

A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis

Erosive Hand Osteoarthritis
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

Healthy

United States
M.D. Anderson Cancer Center
Abbott

Completed

Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer

Head and Neck Cancer

United States
AbbVie

Completed

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

Solid Tumor
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)

Completed

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid

Healthy

United States
Abbott

Completed

A Safety and Tolerability Study of ABT-126 in Elderly

Alzheimer's Disease

United States
Abbott

Completed

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

Hepatitis C

United States
AbbVie (prior sponsor, Abbott)

Completed

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

Advanced Solid Tumors

Australia
Linnaeus University
Kronoberg County Council; Capio Group

Completed

PCBH With the Addition of Self-help CBT

Quality of Life | Stress | Insomnia | Psychological Distress | Depression, Anxiety | Activities, Daily Living

Sweden
University of California, San Francisco
National Institute of Mental Health (NIMH)

Completed

An Adaptive Intervention for Depression Among Latinos Living With HIV (Latino-SMART)

Depression

United States
AbbVie (prior sponsor, Abbott)

Terminated

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Poland, Russian Federation, South Africa, Ukraine, United Kingdom
AbbVie

Terminated

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Schizophrenia

United States, Russian Federation, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian

Netherlands
AbbVie

Terminated

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia
AbbVie

Completed

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Relative Bioavailability

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Hepatitis C Virus Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Abbott

Terminated

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Alzheimer's Disease

United States
Abbott

Terminated

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
Abbott

Completed

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Premature Birth | Congenital Heart Disease | Bronchopulmonary Dysplasia | Respiratory Syncytial Virus Infection

Russian Federation
AbbVie

Completed

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

HCV Infection
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

Sleep Disorder

United States
Abbott

Terminated

An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

Schizophrenia

United States, Argentina, Mexico
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults

Hepatitis C

Japan
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Dose of ABT-333 in Healthy Male Adults

HCV Infections

Japan
Abbott

Completed

Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

Hepatitis C

United States
Abbott

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

HCV Infection

United States
AbbVie

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan

3

Subscribe